Literature DB >> 2825857

[Chemo-radiotherapy combination in small cell bronchial carcinomas. Limitations and results in 109 patients treated with an alternating protocol].

T Le Chevalier1, R Arriagada, P Baldeyrou, H de Cremoux, P Ruffié, M Martin, M L Cerrina, G de Thé, H Sancho-Garnier, M Hayat.   

Abstract

One hundred and nine patients with limited small cell lung carcinoma were entered in a phase II study alternating six cycles of combination chemotherapy and three courses of mediastinal radiotherapy. Chemotherapy consisted of doxorubicin 40 mg/m2 day 1, etoposide 75 mg/m2 days 1, 2, 3, cyclophosphamide 300 mg/m2 days 3, 4, 5, 6, and methotrexate 400 mg/m2 day 2 (+folinic acid rescue) or cisplatin 100 mg/m2 day 2. The total mediastinal radiation dose was 45 or 55 Gy. A 6 to 8 cycle maintenance chemotherapy followed this induction protocol. The complete remission rate at the end of the induction therapy was 79%. The local recurrence rate was 25% and the distant metastases rate was 52%. Median survival is 17.2 +/- 1.2 months and survival rate at 3 years is 26%. Lethal toxicity occurred in 3% of patients during induction therapy, and long term survivors are being evaluated. Our results justify further investigations with this alternating schedule.

Entities:  

Mesh:

Year:  1987        PMID: 2825857

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Surgical resection for small cell lung cancer.

Authors:  D Girling; D Machin; R J Stephens
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

2.  Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.

Authors:  N M Bleehen; D J Girling; A Gregor; R C Leonard; D Machin; C G McKenzie; D A Morgan; J F Smyth; M F Spittle; R J Stephens
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

3.  A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party.

Authors:  N M Bleehen; D J Girling; A Gregor; R C Leonard; D Machin; C G McKenzie; D A Morgan; J F Smyth; M F Spittle; R J Stephens
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.